Mast cells, eosinophils and IgE-positive cells in the nasal mucose of patients with vasomotor rhinitis - An immunohistochemical study by Blom, H.M. (Henk) et al.
Eur Arch Otorhinolaryngol (1995) 252 (Suppl. 1) : $33-$39 9 Springer-Verlag 1995 
H. M. Blom 9 T. Godthelp 9 W. J. Fokkens 9 A. Klein Jan 
A. F. Ho lm.  T. M. Vroom 9 E. Rijntjes 
Mast cells, eosinophils and IgE-positive cells in the nasal mucosa 
of patients with vasomotor rhinitis 
An immunohistochemical study 
Received: 15 April 1994 
Abstract  Vasomotor rhinitis (VMR) is a disorder of un- 
known pathogenesis. Forty patients with VMR were 
carefully selected on the basis of inclusion and exclusion 
criteria proposed by Mygind and Weeke. Nasal biopsy 
specimens were taken in the patient group as well as in a 
group of ten controls. Brush cytology was also taken in 
the VMR group. Inflammatory cells were identified and 
counted in the nasal mucosa, with the use of immunohis- 
tochemical techniques and a panel of monoclonal anti- 
bodies. Eosinophils were studied with the use of BMK13, 
EG2, and Giemsa. Mast cells were studied with anti-chy- 
mase (B7), anti-tryptase (G3) and toluidine blue. Sections 
were stained with IgE as well. There was no significant 
difference in the number of eosinophils, mast cells and 
IgE-positive cells between the two groups. Additionally, 
in contrast with other reports, in sections that were 
double-stained with anti-chymase and anti-tryptase, single 
chymase-positive c lls were found. 
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Introduction 
Rhinitis is subdivided into a number of different entities, 
one of which is vasomotor rhinitis (VMR) [12]. This term 
usually describes a chronic type of rhinitis with nasal con- 
gestion, rhinorrhea and sneezing for which no plausible 
explanation can be found. In 1981 VMR was subcatego- 
rized based on nasal eosinophilia nd the term "NARES" 
(non-allergic rhinitis with eosinophilia syndrome) was in- 
troduced [7]. 
By its nature as a diagnosis by exclusion, VMR represents 
a heterogeneous group of pathophysiological conditions. 
Faced with this group of patients with non-atopic nasal 
complaints, we excluded all patients with systemic, medical, 
and anatomical disorders that could explain complaints of 
rhinorrhea, sneezing, and nasal obstruction. This group with 
unexplainable nasal complaints was then homogenized on 
the basis of a daily record chart on which patients had to 
reach a minimum symptom score. The minimum was set 
using as a basis the definition of rhinitis put forward by 
Mygind and Wihl [25] in 1985. In affected patients periods 
of nasal discharge, sneezing and congestion had to persist 
for an average of at least 30 min to 1 h per day. 
Since VMR, according to prevailing theory, is thought 
to be the result of a neurogenic disorder [8], various au- 
thors have focussed on the neurogenic system by study- 
ing, for example, nasal mucosal innervation or neuropep- 
tide distribution [26]. Others have examined functional 
aspects using such provocational gents as histamine and 
metacholine [5], neuropeptides [26], and non-pharmaco- 
logical agents such as cold, dry air [23], saline solutions 
and iso-osmolar ultrasound mist. Different therapeutic 
regimens including such treatments as topical steroids 
[18], ipatropium bromide [1], and various surgical inter- 
ventions [9, 16, 19] have been studied as well. 
In the present study we investigated the cellular infil- 
trates in the nasal mucosa of patients with a known VMR. 
To our knowledge, this subject has not been addressed be- 
fore. It is well known that in atopic rhinitis, for example, 
cells such as eosinophils, mast cells, antigen presenting 
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Table 1 Criteria for the selection of patients with vasomotor 
rhinitis (VMR) 
Inclusion criteria 
- Age between 16 and 65 years 
- Negative skin prick test and negative RAST score 
- Symptoms for more than 1 year 
- A cumulative score of 5 or more for the following nasal 
parameters: 
blockage, clear discharge and sneezing for at least 7 days 
during a period of 14 days. 
Exclusion criteria 
- The use of systemic or inhaled corticosteroids within the 
previous month 
- The use of inhaled sodium cromoglycate or nedocromil 
sodium within the previous month 
- The use of astemizole within the previous month 
- Inability of the patient o stop taking therapy 
affecting nasal function 
- A serious and/or unstable disease 
- Nasal surgery within the previous 3 months 
- Significant anatomical abnormalities affecting nasal function 
- Nasal polyps or a history of nasal polyps 
- Nasal or paranasal sinus infection 
- Abnormal sinus X-ray 
- Pregnancy or lactation 
- Abnormal aboratory results for: 
blood: Na, K, Ca, total protein, albumin, urea creatinine, 
bilirubin, alkaline phosphatase, aspartate aminotransferase, 
alanine aminotransferase, gamma glutamyl transpeptidase, 
hemoglobin, red blood cell count, plasma cell volume, mean 
corpuscular volume, platelets, total white blood cell count, 
neutrophils, lymphocytes, monocytes, eosinophils, basophils 
urine: blood, protein, glucose 
- Abnormal findings at physical examination 
cel ls and T-cel ls present in the nasal mucosa  are invo lved  
in the pathogenes is  and sustaining of  this d isorder  [4, 11 ]. 
To study the cel lu lar  inf i ltrates in the nasal  mucosa  we 
took brush samples  f rom VMR patients and b iopsy sam- 
ples f rom both VMR patients and controls.  B iops ies  were  
then studied for the presence,  local izat ion,  and act ivat ion 
state of  eos inophi ls  as wel l  as the occurrence and local-  
izat ion o f  mast  cel ls and other surface IgE-pos i t ive  cells. 
Materials and methods 
Patients were studied from 1988 to 1992 in the outpatient ENT De- 
partment of Leyenburg Hospital in The Hague, The Netherlands. 
Patients were admitted to the study if they had a history of nasal 
complaints uch as nasal obstruction, sneezing, and rhinorrhea for 
a period of more than 1 year and these symptoms could not be at- 
tributed to an atopic rhinitis, nasal or paranasal sinus infection, 
anatomical disorders affecting nasal function, pregnancy or lacta- 
tion and/or systemic disorders (Table 1). Patients with nasal polyps 
were also excluded, since they may belong to a different patho- 
physiological group and their polyps may contribute to a higher 
symptom score for nasal blockage and/or rhinorrhea. Of those in- 
dividuals selected, 155 patients cored their nasal complaints for a 
period of 2 weeks using our daily record chart (DRC) (Table 2). 
The duration of complaints during the day was then used as the 
prime criterion for further study [25]. Patients had to have a cumu- 
lative score of 5 or more for the following nasal parameters: block- 
age, clear nasal discharge, and sneezing for at least 7 days during 
a period of 14 days. Forty of the 155 patients were found eligible 
for our study and participated under conditions of informed con- 
sent. 
A nasal brush sample for cytology and a mucosal biopsy spec- 
imen were taken from all 40 patients. Ten healthy volunteers with- 
out nasal complaints or nasal abnormalities on ENT examination 
and a negative skin prick test were biopsied once and tissue speci- 
mens used as controls. 
Nasal biopsies 
At the time of biopsy, all patients had nasal complaints, as con- 
firmed by their DRCs. After randomization of the biopsy side, 
specimens of nasal mucosa were taken from the lower edge of the 
inferior turbinate, about 2 cm posterior to the front edge, using a 
Gerritsma forceps with a cup diameter of 2.5 mm [3]. 
Local anesthesia was obtained by placing a cotton-wool carrier 
with 50 mg cocaine and one drop of adrenaline (1 : 1000) under the 
inferior turbinate but without touching the biopsy site. The speci- 
mens were embedded in Tissue-Tek II O.C.T. compound and 
frozen immediately. 
Nasal brush cytology 
Contralateral to the biopsy side a nasal brush sample was taken 
from the middle nasal fossa using the Gynobmsh (Medeco, Eind- 
hoven, The Netherlands). This is a modification of the technique 
advocated by Pipkorn [10]. In our experience, this brush is less 
painful than the Rhinobrush (also Medeco). The brush was imme- 
diately placed in RPMI. Within 3 days cytospin preparations were 
made and cells were stained with Giemsa and toluidine blue. 
Table 2 Scheme of the daily 
record chart for defining nasal 
symptoms in patients with va- 
somotor hinitis 
Remarks: All other medical 
complaints and medication 
taken during the day should be 
noted 
Possible scores on the daily record chart 
Nasal blockage 
(not being able to breathe freely through the nose): 
Clear nasal discharge (runny nose): 
Sneezing: 
Coughing: 
Mucus production (yellow, green or brown): 
0 = absent 
1 = between O-1 h per half day 
2 = between 1-2 h pe r half day 
3 = more than 2 h per half day 
0 = absent 
1 = less than 5 periods per half day 
2 = between 5-10 periods per half day 
3 = more than 10 periods per half day 
0 = absent 
1 = present 
Table 3 Monoclonal anti- 
bodies and histochemical dyes 
used to study mucosal biopsies 
in patients with VMR and 
controls (MBP major basic 
protein, ECP eosinophilic 
cationic protein) 
Antibody Titer Specificity Source 
BMK 13 1:200 MBP 
EG2 1 : 40 ECP 
c~-IgE 1 : 250 IgE 
B7 1 : 100 Chymase 
G3 1 : 250 Tryptase 
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Sanbio, Uden, The Netherlands (NL) 
Pharmacia, Woerden, NL 
Central Laboratory of The Netherlands Red Cross 
Blood Transfusion Service (CLB), Amsterdam, NL 
Chemicon, Temecula, Calif, USA 
Cehmicon, Temecula, Calif, USA 
Histochemical dyes Source 
Giemsa Merck, Amsterdam, NL 
Toluidine blue B.D.H, Dorset, UK 
Staining procedures 
Eosinophils 
The monoclonal antibodies (mAb) BMK13, EG2 and Giemsa 
(Table 3) were used together with the immuno-alkaline phos- 
phatase, anti-alkaline phosphatase (APAAP) method. BMK13 is a 
mAb against major basic protein and is reported to stain 95-97% 
of all eosinophils [13]. EG2 is a mAb against eosinophilic cationic 
protein and stains the activated eosinophils [22]. 
Sections of nasal mucosa were cut in 6 gm thicknesses on a 
cryostat (Jung Frigocut 2800E/20/40), transferred topoly-L-lysine- 
coated microscope slides, dried, and fixed in acetone for 10 min at 
20~ They were next rinsed in phosphate-buffered saline (PBS, 
pH 7.2), placed in a half-automatic stainer (Sequenza, Shandon), 
incubated with 2% bovine serum albumin in PBS for 10 min and 
incubated with normal rabbit serum (CLB, Amsterdam, The 
Netherlands) for 10 min. Following this the slides were incubated 
with the mAb for 30 min at 20 ~ C. The sections were then rinsed 
again in PBS for 5 min and incubated for 30 rain with a rabbit anti- 
mouse (1:20) immunoglobulin a tiserum, rinsed successively in
PBS, incubated with APAAP (1:40) (Dakopatts, Copenhagen, 
Denmark) for 30 min at 20 ~ C, rinsed in PBS and TRIS buffer (pH 
8.0), and incubated for 30 min with a new fuchsin substrate 
(Chroma, Kongen, Germany). Finally, sections were rinsed with 
distilled water, counterstained with Mayer's hematoxylin, and 
mounted in glycerin-gelatin. Control staining was performed by 
substitution with PBS and incubation with an irrelevant mAb of 
the same subclass. 
Mast cells 
Toluidine blue, an aniline dye, stains mast cells metachromati- 
cally. Tissue sections were stained with toluidine blue at pH 0.5 
for 5 min and counts were performed immediately [4].The mAbs 
anti-chymase (B7) and anti-tryptase (G3) are mast cell specific 
[6]. To check our atopic screening, the biopsy material was also 
stained with anti-IgE, since atopic patients usually have a large 
number of IgE-positive cells present in biopsy sections [4]. For 
staining with anti-IgE, G3 and B7 (Table 3) supersensitive AP
was used (BioGenex AZ000UM).This protocol followed the 
APAAP protocol up to the first PBS rinse. Sections were then in- 
cubated with normal goat serum (CLB, Amsterdam, The Nether- 
lands) for 10 min and then for 60 min with the mAb. The sec- 
tions were rinsed with PBS for 5 min and succesively inked with 
biotinylated anti-mouse serum for 30 min, rinsed with PBS for 5 
miu, and labeled with streptavidin-AP (ssAP) for 30 min. They 
were next rinsed in PBS for 5 min and TRIS buffer (pH 8.0) for 
5 min, and then incubated for 30 min with new fuchsin, after 
which the protocol again conformed to the APAAP protocol. 
Furthermore, for a general evaluation and control counting of 
eosinophils, hematoxylin-eosin (HE) and Giemsa staining were 
performed. 
Double staining of mast cells was achieved by incubation with 
anti-chymase, linked with biotinylated anti-mouse and labeled 
with steptavidin f3-D-galactoside for 60 min. The sections were 
then incubated with anti-tryptase AP for 60 min, after which sam- 
ples were incubated with ~-D-galactoside substrate and new 
fuchsin substrate. Slides were mounted in glycerin. 
Light-microscopic evaluation 
Stained cells were counted in two sections of each biopsy speci- 
men. The epithelium and lamina propria were evaluated sepa- 
rately. The total surface area of a section and its main parts (i.e., 
the epithelium and lamina propria) were estimated with the use of 
the Kontron Image Analysis System Videoplan. The number of 
cells/ram 2 was calculated for the epithelium and the lamina propria. 
Statistical analysis 
The Mann-Whitney U-test was used to compare the differences in 
cell counts between the groups. A P value < 0.05 was considered 
to indicate a significant difference. 
Results 
Biopsy specimens 
The sections of nasal mucosa had an average surface area 
of 1.5 mm 2 and were generally of good quality. All but 
two biopsy specimens were evaluated. One exclusion was 
made because of artifact resulting from defrosting of the 
specimen and the other specimen was displaced. The 
mAb-APAAP and the mAb-ssAP staining showed red 
cells against a blue counterstained background. After tolu- 
idine-blue staining, mast cells could easily be identified 
by their dark-violet, metachromatic granules against a 
background of faintly stained tissue. 
Eosinophils 
The numbers of Giemsa-positive, BMK13-posit ive and 
EG2-posit ive cells/mm 2 are shown in Table 4. Virtually 
no eosinophils were present in the lamina propria and the 
epithelium of both groups and any differences between 
the two groups were not statistically significant. 
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Table 4 Median and range (..) 
of numbers of eosinophils, 
mast cells and other IgE-posi- 
tire cells in the nasal mucosa 
of patients with vasomotor 
rhinitis and controls 
Eosinophils Patients (n = 40) Controls (n = 10) P value 
Median (range) Median (range) 
Epithelium 
BMK13 0 (0-281) 0 (0-53) Not significant 
EG2 0 (0-128) 0 (0) Not significant 
Giemsa 0 (0-209) 0 (0-9) Not significant 
Lamina propria 
BMK13 0 (0-350) 0 (0-6) Not significant 
EG2 0 (0-56) 0 (0) Not significant 
Giemsa 0 (0-124) 0 (0-1) Not significant 
Mast cells and IgE + cells Patients (n --- 40) Controls (n = 10) P value 
Median (range) Median (range) 
Epithelium 
Toluidine blue 0 (0-138) 
Anti-tryptase 0 (0-282) 
Anti-chymase 0 (0-40) 
Anti-IgE 0 (0-480) 
Lamina propria 
Toluidine blue 22 (0-101) 
Anti-tryptase 74 (1-162) 
Anti-chymase 75 (25-238) 
Anti-IgE 21 (0-338) 
0 (0-4) Not significant 
0 (0-29) Not significant 
0 (0-3) Not significant 
0 (0-198) Not significant 
17 (19-51) Not significant 
70 (9-96) Not significant 
54 (24-83) Not significant 
7 (0-152) Not significant 
Mast cells and other IgE-positive cells 
The numbers of toluidine-blue-positive, G3-positive, B7- 
positive and anti-IgE positive cells/mm 2 are shown in 
Fig. 1. The number of B7-positive cells tended to be higher 
than the number of G3-positive cells in both patients and 
controls. Both tended to be higher than the number of 
toluidine-blue-positive c lls. There were no significant 
differences between the two groups as to cell numbers in 
the epithelium and lamina propria (Fig. 2) for the various 
staining methods. Biopsy specimens from 2 of 40 patients 
showed substantial numbers of eosinophils, mast cells, 
and IgE-positive cells. 
Brush material 
A total of 500 cells were counted per cytospin. Toluidine- 
blue-positive cells were found in just one cytopsin (50 
toluidine-blue-positive cells per 500 counted cells). 
Eosinophils were not found. 
Discussion 
We selected 155 patients with a history of nasal com- 
plaints for which no explanation could be found. How- 
ever, only 40 of these patients atisfied our condition for 
inclusion in our study of nasal complaints for more than 
1 h a day. That patients often overestimate nasal complaints 
underscores the importance of the use of DRCs to charac- 
terize patients objectively. The duration of complaints was 
used as our prime criterion. It is also common knowledge 
that subjective complaint scores in which the intensity of 
the complaints are graded can be influenced by a patient's 
state of mind. On a bad day, patients uffer more. More- 
over, it is easier for a patient o score the duration of the 
complaints than to grade intensity. 
Biopsies from two patients with VMR had substantial 
numbers of IgE-positive cells, mast cells, and eosinophils. 
As a consequence, we feel that these patients were indeed 
allergic in spite of their negative allergy tests. The data of 
these two patients were included since they satisfied our 
overall inclusion criteria. 
Brush cytology 
VMR patients with prominent nasal eosinophilia of 20% 
or more are subcategorized asNARES patients. In general 
the NARES group comprises 10-13% of the VMR pa- 
tients [14]. Contrary to expectations, none of our patients 
showed eosinophilia in cytospin preparations of brush 
samples. This might be explained by the eosinophilic sub- 
group being more susceptible to therapy [20]. The use of 
nasal corticosteroids has gained increasing acceptance by 
the general practitioner during the last decade. It is thus 
possible that most NARES patients are less symptomatic 
with nasal corticosteroid spray and are therefore not re- 
ferred to the ENT surgeon for further care. This hypothe- 
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Fig.IA-C Serial sections of nasal mucosal biopsies. A Nasal 
mucosa stained with anti-chymase. B Nasal mucosa stained with 
anti-tryptase. C Nasal mucosa stained with anti-chymase (green) 
and anti-tryptase (r d). Single anti-chymase cells are indicated by 
squares. Single anti-tryptase cells are indicated by triangles. The 
sections are slightly counterstained with hematoxylin and eosin. 
x 170 
sis is supported by the finding in our group of patients that 
congestion was the primary symptom, In NARES patients 
sneezing and clear rhinorrhea re the main symptoms. 
Moreover, although in the eosinophilic subgroup olyps 
are seen clinically in 30% of cases, polyps were an exclu- 
sion criterion in our series. 
Biopsy specimens 
Eosinophils 
Since virtually no eosinophils were found with Giemsa or 
BMK13, not to mention activated eosinophils ( .e., EG2- 
positive cells), in biopsy specimens from our patients and 
controls, we currently believe that these cells are not im- 
portant in the pathogenesis of VMR, excluding NARES. 
Mast cells 
Anti-tryptase is reported to stain all mast cells while some 
of these tryptase-positivie c lls are also positive for chy- 
mase [6]. Contrary to our expectation, the number of chy- 
mase-positive cells was not lower than the number of 
tryptase-positive c lls in our present study. Additionally, 
in sections that were double-stained with anti-chymase 
and anti-tryptase, single chymase-positive c lls were 
found (Fig. 1). We think that this is the result of our fixa- 
tion method. While other authors all use Carnoy's solu- 
tion for mast cell fixation, we fixed our sections with ace- 
tone. We then found fixation with Carnoy's olution dras- 
tically reduced the numbers of chymase-positive and tolu- 
idine-blue-positive c lls, whereas the number of tryptase- 
positive cells was only slightly reduced. We therefore pre- 
fer acetone fixation. 
Apart from the two biopsies that were previously men- 
tioned, virtually no mast cells were found in the nasal ep- 
ithelium from controls and patients. As reported by 
Okuda et al. [17] the predominant metachromatic cell in 
the lamina propria of the nasal mucosa is the mast cell, the 
basophilic neutrophil that can also be stained with tolui- 
dine blue, is generally not present in the lamina propria 
of the nasal mucosa. This is in accordance with our find- 
ings. 
To our surprise we found no evidence for mast cell in- 
volvement in VMR. In allergic rhinitis cross-linking of 
IgE on the membrane of the mast cells and the subsequent 
release of mast cell mediators (degranulation) is thought 
to contribute substantially to the complaints associated 
with rhinitis. We detected no specific IgE (by RAST and 
skin-prick test) and there was no significant difference in 
the number Of IgE-positive cells between our VMR pa- 
tients and the controls. Apart from the two biopsies with 
substantial numbers of eosinophils, mast cells and anti- 
IgE positive cells, no evidence for degranulation as a re- 
sult of IgE cross-linking was found. Separate studies have 
shown that neuropeptides have been found to induce de- 
granulation in mast cells [2]. Support for neuropeptide in- 
volvement in VMR has been found by investigations 
demonstrating a reduction in nasal complaints associated 
with a depletion of sensory neuropeptides by prior treat- 
ment with capsaicin [21]. A recent study by Lacroix's 
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Fig.2 Mast cells and other 
IgE-positive cells in the lamina 
propria of the nasal mucosa of 
patients with vasomotor rhinitis 
(n = 40) and controls (n= 10). 
Significant differences were 
found between the number of 
toluidine-blue-positive cells 
and the number of anti-chymase- 
positive cells. No significant 
differences were found be- 
tween the number of anti- 
tryptase-positive c lls and the 
number of anti-IgE-positive 
cells. Group median values are 
represented by horizontal bars 
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group [11] also found an increased concentration of sen- 
sory neuropeptides in the nasal mucosa of patients with 
chronic non-allergic rhinitis. 
One could hypothesize that an increased neuropeptide 
content could induce an ongoing degranulation of mast 
cells and thus a release of mast cell mediators, resulting in 
a possible decrease in mast cell numbers. However, a re- 
duction in mast cell numbers was not found in our group 
of patients. Further evaluation of mast cell degranulation 
by electron microscopy studies is in progress. In the near 
future we will report on the involvement of T-cell subsets, 
and other inflammatory cells, including cytokine produc- 
tion. 
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